Cargando…
The history of monoclonal antibody development – Progress, remaining challenges and future innovations
As medicine progresses into a new era of personalised therapy, the use of monoclonal antibodies to treat a wide range of diseases lies at the heart of this new forefront. Since the licencing of the first monoclonal antibody for clinical use 30 years ago, the monoclonal antibody industry has expanded...
Autor principal: | Liu, Justin K.H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284445/ https://www.ncbi.nlm.nih.gov/pubmed/25568796 http://dx.doi.org/10.1016/j.amsu.2014.09.001 |
Ejemplares similares
-
Gastric Organoids: Progress and Remaining Challenges
por: Pang, Min-Jiao, et al.
Publicado: (2021) -
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019) -
Oncolytic viruses as immunotherapy: progress and remaining challenges
por: Aurelian, Laure
Publicado: (2016) -
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
por: Arias-Pinilla, Gustavo A., et al.
Publicado: (2021) -
Liver failure—future challenges and remaining questions
por: Lemmer, Peter, et al.
Publicado: (2021)